Atlas Trials

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

Clinical trial NCT05521438 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05521438
Sponsor
Quoin Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Netherton Syndrome
Start date
2022-06-23
Primary completion
2025-12-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.